Clostridioides difficile: Difference between revisions
From IDWiki
Clostridioides difficile
No edit summary |
m (Aidan moved page Clostridium difficile to Clostridioides difficile) |
(No difference)
| |
Revision as of 10:31, 22 August 2019
Microbiology
- Spore-forming, anaerobic, Gram-positive bacillus
Management
Further Reading
References
- a b Kevin A. Brown, Nagham Khanafer, Nick Daneman, David N. Fisman. Meta-Analysis of Antibiotics and the Risk of Community-Associated Clostridium difficile Infection. Antimicrobial Agents and Chemotherapy. 2013;57(5):2326-2332. doi:10.1128/aac.02176-12.
- a b Vivian G Loo, Ian Davis, John Embil, Gerald A Evans, Susy Hota, Christine Lee, Todd C Lee, Yves Longtin, Thomas Louie, Paul Moayyedi, Susan Poutanen, Andrew E Simor, Theodore Steiner, Nisha Thampi, Louis Valiquette. Association of Medical Microbiology and Infectious Disease Canada treatment practice guidelines for Clostridium difficile infection. Official Journal of the Association of Medical Microbiology and Infectious Disease Canada. 2018;3(2):71-92. doi:10.3138/jammi.2018.02.13.
- ^ Clostridium difficile Infection in Infants and Children. Pediatrics. 2012;131(1):196-200. doi:10.1542/peds.2012-2992.
- ^ Mazen S. Bader, John Hawboldt, Cheryl Main, Dominik Mertz, Mark Loeb, Alison Farrell, Joanna Joyce. Review of high dose vancomycin in the treatment of Clostridioides difficile infection. Infectious Diseases. 2020;52(12):847-857. doi:10.1080/23744235.2020.1800080.
- ^ Steven W Johnson, Shannon V Brown, David H Priest. Effectiveness of Oral Vancomycin for Prevention of Healthcare Facility–Onset Clostridioides difficile Infection in Targeted Patients During Systemic Antibiotic Exposure. Clinical Infectious Diseases. 2019;71(5):1133-1139. doi:10.1093/cid/ciz966.
